The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review
Open accessAbstract
The role of N-acetylcysteine (NAC) in the treatment of chronic bronchitis is unclear. Since a number of studies have been published on this topic, a systematic review of published studies seems justified. A systematic search (Medline, Embase, Cochrane Library, bibliographies, no language restriction) for published randomized trials comparing oral NAC with placebo in patients with chronic bronchitis was performed. Dichotomous data on prevention of exacerbation, improvement of symptoms and adverse effects were extracted from original reports. The relative benefit and number-needed-to-treat were calculated for both individual trials and combined data. Thirty-nine trials were retrieved; eleven (2,011 analysed patients), published 1976-1994, were regarded as relevant and valid according to preset criteria. In nine studies, 351 of 723 (48.5%) patients receiving NAC had no exacerbation compared with 229 of 733 (31.2%) patients receiving placebo (relative benefit 1.56 (95% confidence interval (CI) 1.37-1.77), number-needed-to-treat 5.8 (95% CI 4.5-8.1). There was no evidence of any effect of study period (12-24 weeks) or cumulative dose of NAC on efficacy. In five trials, 286 of 466 (61.4%) patients receiving NAC reported improvement of their symptoms compared with 160 of 462 (34.6%) patients receiving placebo (relative benefit 1.78 (95% CI 1.54-2.05), number-needed-to-treat 3.7 (95% CI 3.0-4.9)). With NAC, 68 of 666 (10.2%) patients reported gastrointestinal adverse effects compared with 73 of 671 (10.9%) taking placebo. With NAC, 79 of 1,207 (6.5%) patients withdrew from the study due to adverse effects, compared with 87 of 1,234 (7.1%) receiving placebo. In conclusion, with treatment periods of approximately 12-24 weeks, oral N-acetylcysteine reduces the risk of exacerbations and improves symptoms in patients with chronic bronchitis compared with placebo, without increasing the risk of adverse effects. Whether this benefit is sufficient to justify the routine and long-term use of N-acetylcysteine in all patients with chronic bronchitis should be addressed in further studies and cost-effectiveness analyses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582
Schulz (1995) · doi:10.1001/jama.1995.03520290060030 · Cited by 5,634
Beta blockade during and after myocardial infarction: An overview of the randomized trials
Yusuf, S., Peto, R., Lewis, J., Collins, R., & Sleight, P. (1985) · Progress in Cardiovascular Diseases · doi:10.1016/s0033-0620(85)80003-7 · Cited by 3,205
The number needed to treat: a clinically useful measure of treatment effect
Cook, R. J., & Sackett, D. L. (1995) · BMJ · doi:10.1136/bmj.310.6977.452 · Cited by 1,885
An Assessment of Clinically Useful Measures of the Consequences of Treatment
Laupacis, A., Sackett, D. L., & Roberts, R. S. (1988) · New England Journal of Medicine · doi:10.1056/nejm198806303182605 · Cited by 1,681 · cited 1×
“A statistically significant difference between NAC and control was assumed when the 95% CI of the relative benefit or risk did not include 1. As an estimate of the clinical relevance of a treatment effect, the number-needed-to-treat [ 16 ] was calculated for both individual trials and combined data.”
MethodImpact of covert duplicate publication on meta-analysis: a case study
Tramèr, M. R., Reynolds, D. J. M., Moore, R. A., & McQuay, H. J. (1997) · BMJ · doi:10.1136/bmj.315.7109.635 · Cited by 702
Self-citation
Cited by
N-Acetylcysteine—a safe antidote for cysteine/glutathione deficiency
Atkuri, K. R., Mantovani, J. J., Herzenberg, L. A., & Herzenberg, L. A. (2007) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2007.04.005 · Cited by 721
Rushworth, G. F., & Megson, I. L. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.09.006 · Cited by 719
Decramer, M., Rutten-van Mölken, M., Dekhuijzen, P. R., Troosters, T., van Herwaarden, C., Pellegrino, R., van Schayck, C. O., Olivieri, D., Del Donno, M., De Backer, W., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66456-2 · Cited by 684
COPD exacerbations: definitions and classifications
Burge, S., & Wedzicha, J. A. (2003) · European Respiratory Journal · doi:10.1183/09031936.03.00078002 · Cited by 664
Oxidative stress and lung inflammation in airways disease
MacNee, W. (2001) · European Journal of Pharmacology · doi:10.1016/s0014-2999(01)01320-6 · Cited by 556
Metadata
- Authors
- Stey, C., Steurer, J., Bachmann, S., Medici, T. C., & Tramèr, M. R.
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 2000-08
- Volume
- 16
- Issue
- 2
- Pages
- 253
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- OpenAlex
- W2135682290
- Cited by
- 284
- References
- 6
- FWCI
- 2.97
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review. https://app.cochat.ai/papers/10.1034/j.1399-3003.2000.16b12.x
- The paper
- Stey, C., Steurer, J., Bachmann, S., Medici, T. C., & Tramèr, M. R. (2000). The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review. European Respiratory Journal. https://doi.org/10.1034/j.1399-3003.2000.16b12.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.